2. Signaling Pathways
  3. GPCR/G Protein
  4. GPR109A
  5. GPR109A Agonist

GPR109A Agonist

GPR109A Agonists (11):

Cat. No. Product Name Effect Purity
  • HY-103252
    Monomethyl fumarate
    		Agonist 99.95%
    Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease.
  • HY-10680
    MK-6892
    		Agonist 99.43%
    MK-6892 is a potent, selective, and full agonist for the high affinity nicotinic acid (NA) receptor GPR109A. Ki and GTPγS EC50 of MK-6892 on the Human GPR109A is 4 nM and 16 nM, respectively.
  • HY-13008
    MK-0354
    		Agonist 99.73%
    MK-0354 is a partial agonist of GPR109a receptor, for hGPR109a/ mGPR109a with EC50 of 1.65/1.08 μM, showed no activation of GPR109b.
  • HY-119222
    GSK256073
    		Agonist 99.11%
    GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
  • HY-103252R
    Monomethyl fumarate (Standard)
    		Agonist
  • HY-107579R
    Acifran (Standard)
    		Agonist
    (2S,5R,6R)-Ticarcillin (disodium) (Standard) is the analytical standard of (2S,5R,6R)-Ticarcillin (disodium). This product is intended for research and analytical applications. (2S,5R,6R)-Ticarcillin disodium is an injectable antibiotic for the treatment of Gram-negative bacteria, particularly Pseudomonas aeruginosa. It is also one of the few antibiotics capable of treating Stenotrophomonas maltophilia infections.
  • HY-107579
    Acifran
    		Agonist 99.25%
    Acifran (AY 25712), an antihyperlipidemic agent, is an orally active agonist of GPR109A (HM74A) and GPR109B, the high and low affinity receptors for Niacin.
  • HY-W095200
    GPR109 receptor agonist-2
    		Agonist 99.08%
    GPR109 receptor agonist-2 (Compound 5) is a selective GPR109a agonist with a pEC50 of 5.53.
  • HY-107580
    GPR109 receptor agonist-1
    		Agonist 99.91%
    GPR109 receptor agonist-1 (Compound 3a) is a highly selective agonist of the human orphan G-protein-coupled receptor GPR109b, with the pEC50 of 6.4. GPR109 receptor agonist-1 can be used for the research of cardio-metabolic diseases.
  • HY-103252S1
    Monomethyl fumarate-d5
    		Agonist
    Monomethyl fumarate-d5 is deuterium labeled Monomethyl fumarate. Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease[1][2][3].
  • HY-119222A
    GSK256073 tris
    		Agonist
    GSK256073 tris is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 tris acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2